Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and...

Descripción completa

Detalles Bibliográficos
Autores principales: Friend, Reed, Bhutani, Manisha, Voorhees, Peter M, Usmani, Saad Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367738/
https://www.ncbi.nlm.nih.gov/pubmed/28356715
http://dx.doi.org/10.2147/DDDT.S98053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367738/
https://www.ncbi.nlm.nih.gov/pubmed/28356715
http://dx.doi.org/10.2147/DDDT.S98053

Ejemplares similares